Navigation Links
VIVUS Reports Topline Findings From FORTRESS
Date:12/21/2011

and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >/=30 kg/m2), or overweight patients (BMI >/=27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
2. VIVUS Resubmits Qnexa NDA to the FDA
3. VIVUS Provides Regulatory Update on QNEXA
4. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
5. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
6. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
7. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
8. VIVUS to Present at Three Upcoming Investor Conferences in March
9. VIVUS Provides Regulatory Update on QNEXA NDA
10. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
11. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation ... conference call on Tuesday, August 5, 2014, at 8:30 ... second quarter 2014 financial results. An audio ... through the Investor Relations portion of the CVS Caremark ... visit http://info.cvscaremark.com/investors . This webcast will be archived ...
(Date:7/25/2014)... 2014  Acsis Inc., the market leader for ... has recently posted an article, "Future of ... future needs for companies, extended supply chain, and ... model no longer work today.  The article explains ... of mobile technology, machine to machine (M2M) connectivity, ...
(Date:7/25/2014)... Research and Markets has announced the addition ... report to their offering. ... An ophthalmic diagnostic device is a ... in the human visual pathway. Ophthalmic devices are used ... glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... on Mayo Clinic Discoveries is Developing Therapies for Wounds, ... Angiogenic Properties , , ... company,s novel technology platform which employs nano-materials made of ... wound healing, diabetic foot ulcers and hair growth are ...
... Dec. 14 Eisai Corporation of North,America today ... (FDA) has,approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous,sedative-hypnotic ... adult,patients undergoing diagnostic or therapeutic procedures. , ... the FDA required that LUSEDRA be used only ...
Cached Medicine Technology:OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 2OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 2FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 4
(Date:7/27/2014)... 2014 Bags underneath the eyes is one ... and there are a range of new products now available ... a baggy eyes serum review that is now posted for ... explores the issues with baggy eyes and how the natural ... users. The guide also provides a detailed overview of the ...
(Date:7/27/2014)... hepatitis E virus (HEV) transmission by blood components indicates ... HEV in their plasma. The findings, published in ... components (eg, red cells, platelets, and fresh frozen plasma) ... , The study retrospectively screened 225 000 individual ... 2012 and Sept, 2013 for HEV RNA. 79 donors ...
(Date:7/27/2014)... Ticket Down is a reputable source for ... California on November 15th. This Australian boy band has recently ... songs from this amazing album at the concert. , Tickets ... The Forum will be released for sale to the general public ... TicketDown.com. This popular secondary ticket exchange can also be reached ...
(Date:7/27/2014)... According to a new market report ... Endoscopic Operative Devices, and Visualization Systems) - Global Industry ... global endoscopy devices market was valued at USD 24.9 ... a CAGR of 6.8% from 2013 to 2019, to ... 2019. , Endoscopy procedures are performed by inserting rod ...
(Date:7/27/2014)... Scientists from The University of Manchester have discovered why medication ... findings, published in Nature Medicine , show that drugs ... clock. , In the UK pneumonia, which is ... each year and is more serious for babies, young children, ... , More than 5 million people in the UK ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Drugs used to treat lung disease work with the body clock 2
... Directors and Commits all ... Work to Benefit FASTeam, CHICAGO, July 7 Fetal ... Bifida, Down Syndrome and Muscular,Dystrophy combined, yet it is a ... prevention of prenatal alcohol exposure and,research examining the effects of ...
... play a major role in,keeping the bone marrow environment ... Tenn., July 7 The lack of a single,protein ... to,recycle molecules in cells causes an incurable and often ... Hospital investigators., Children with this disease, called sialidosis, ...
... chances of miscarriage for couple, study finds , , MONDAY, ... those in which the man is over age 35 have ... study shows. , To come to this conclusion, French researchers ... fertility clinic in France. , In most of the cases, ...
... San Francisco,s Largest AIDS Fundraising Event Goes GREEN with Online ... Communications, Recycling and Awareness, ... AIDS Walk San Francisco announced today key initiatives to ,Green, ... The,initiatives include the introduction of Green Walkers, composting, and,enhanced recycling., ...
... Athens Regional Medical Center and,Blue Cross and Blue ... multi-year contract, enabling Athens Regional to join the BCBSGa,HMO/POS ... PPO contract with,Athens Regional for many years., The ... throughout,Georgia will be able to gain complete access to ...
... Physicians Practice, America,s,Leading Practice Management Journal today ... to editorial director, Steven Gottshall to associate,publisher, ... promotions,are reflective of the company,s overall strategy ... into new physician focused markets and,circulation growth., ...
Cached Medicine News:Health News:K Squared Sponsors F.A.S.T. Ride 150-mile Motorcycle Tour August 17 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 3Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 4Health News:Father's Age a Factor in Infertility 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 3Health News:Blue Cross and Blue Shield of Georgia and Athens Regional Medical Center Announce New HMO/POS Contract 2Health News:Physicians Practice Promotes Key Executives 2
... Pupillometry in Critical Care & Emergency ... a hand-held, cordless, and simple to use ... the measurement of the pupillary light reflex ... pupillary function which are not discernable to ...
...
Inquire...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
Medicine Products: